tbuckley/cabot-search huggingface dataset:
AB1082 Characterisation of a group of patients with igg4-related disease: single centre experience
Authors: A. Kozlova, V. Burlakov, D. Abramov, A. Laberko, G. Sagoyan, A. Shcherbina
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Immunoglobulin G4-related disease (IgG4-RD) is a chronic systemic inflammatory condition with an unclear pathophysiology and IgG4-positive plasma cells infiltration of various organs and parts of the body. If untreated, the disease can lead to fibrosis and irreversible organ damage. IgG4-RD mostly has been described in adults, hence it is generally unknown among paediatricians. <h3>Objectives</h3> We conducted a retrospective analysis of clinical features and response to therapy of five patients (one female, four males, median age 13,6 years) with IgG4-related disease, treated in our Centre. <h3>Methods</h3> The diagnosis was confirmed by detection of lymphoplasmacytoid infiltration with &gt;30% of cells expressing IgG4 in all, and elevated IgG4 serum concentration in 4 cases. <h3>Results</h3> Three patients had localised lesions (orbit, hip muscle, peripancreatic tissue, respectively), two – multi-organ disease with polylymphadenopathy, pulmonary, renal and hepatic foci, dacryoadenitis with oedema of the eyelids. Autoimmune thrombocytopenia (70 × 10<sup>9</sup>/l), neutropenia (0,79 × 10<sup>9</sup>/l) were present in one patient. Rituximab therapy was successful in 2 cases (one patient received monotherapy with rituximab, another one – Rituximab and Sirolimus). Two other patients received JAK inhibitor therapy (ruxolitinib) with good effect. No side effects were noted. One patient underwent surgery – the infiltration in the abdominal cavity was removed with positive effect without specific therapy. <h3>Conclusions</h3> IgG4-RD symptoms can be diverse and sometimes atypical, so dealing with this pathology requires physician's awareness. Rituximab was effective in patients with multi-organ manifestations, and JAK inhibitor (Ruxolitinib) was effective in patients with mono-focal disease. Steroids are routinely used in IgG4-RD as a first line of treatment with significant side effects. We propose that alternative drugs could be used in IgG4-RD, especially in paediatric patients to achieve fast remission with significant morbidity. <h3>Disclosure of Interest</h3> None declared
Abstract SY11-03: Turning enzymes on with small molecules
Authors: James A. Wells, Dennis Wolan, Julie Zorn, Debajyoti Datta, Daniel Gray, Jack Sadowsky
Journal: Cancer Research (2010)

Abstract Most drug discovery efforts focus on generating inhibitors leading to loss-of-function phenotypes. My lab has been focusing on discovering ways to activate enzymes leading to gain-of-function phenotypes. Many enzymes such as proteases and kinases are stored in dormant “off” forms that are subsequently activated through post-translational modification. Work will be presented for discovery of small molecule activators for the apoptotic proteases known as caspases, as well a Ser-Thr kinase PDK-1. Our group is also developing split-proteins that can be activated by orthogonal small molecule dimerizers to phenocopy the effects seen from the small molecule activators. Such protein activators allow one to ignite signaling from specific nodes and thus probe the sufficiency of enzyme activity to drive a cellular response. Protein activation, as opposed to inhibition, expands the landscape for drug discovery. Citation Format: James A. Wells, Dennis Wolan, Julie Zorn, Debajyoti Datta, Daniel Gray, Jack Sadowsky. Turning enzymes on with small molecules [abstract]. In: Proceedings of the AACR 101st Annual Meeting 2010; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr SY11-03
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
Authors: Elena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, Eduard Monsó, Laura Millares, Enriqueta Felip, Rafael Rosell, José Luis Ramirez, Ana Remirez, Wenceslao Torre, Ignacio Gil-Bazo, Miguel A Idoate, Juan P de-Torres, Ruben Pio, Ignacio I Wistuba, María J Pajares, Luis M Montuenga
Journal: Thorax (2018)

Introduction Prognostic biomarkers have been very elusive in the lung squamous cell carcinoma (SCC) and none is currently being used in the clinical setting. We aimed to identify and validate the clinical utility of a protein-based prognostic signature to stratify patients with early lung SCC according to their risk of recurrence or death. Methods Patients were staged following the new International Association for the Study of Lung Cancer (IASLC) staging criteria (eighth edition, 2018). Three independent retrospective cohorts of 117, 96 and 105 patients with lung SCC were analysed to develop and validate a prognostic signature based on immunohistochemistry for five proteins. Results We identified a five protein-based signature whose prognostic index (PI) was an independent and significant predictor of disease-free survival (DFS) (p&lt;0.001; HR=4.06, 95% CI 2.18 to 7.56) and overall survival (OS) (p=0.004; HR=2.38, 95% CI 1.32 to 4.31). The prognostic capability of PI was confirmed in an external multi-institutional cohort for DFS (p=0.042; HR=2.01, 95% CI 1.03 to 3.94) and for OS (p=0.031; HR=2.29, 95% CI 1.08 to 4.86). Moreover, PI added complementary information to the newly established IASLC TNM 8th edition staging system. A combined prognostic model including both molecular and anatomical (TNM) criteria improved the risk stratification in both cohorts (p&lt;0.05). Conclusion We have identified and validated a clinically feasible protein-based prognostic model that complements the updated TNM system allowing more accurate risk stratification. This signature may be used as an advantageous tool to improve the clinical management of the patients, allowing the reduction of lung SCC mortality through a more accurate knowledge of the patient’s potential outcome.
Differential modes of action of cisplatin and oxaliplatin: Involvement of NO and reactive oxygen in induction of apoptosis
Authors: Maria Shoshan, Maria Berndtsson, Claudia Burz, Emma Hernlund, Özgur Kutuk, Elin Jerremalm, Aris Panaretakis, Stig Linder
Journal: Cancer Research (2005)

5329  Cisplatin (cDDP) and oxaliplatin (OXP) are typically regarded as DNA-damaging agents. We and others have shown that they induce apoptosis independently of DNA. However, their differing spectra of clinical use and side effects indicate differential modes of action. We have here examined and compared apoptotic signal transduction induced by these two drugs with the aim to better understand their cytoplasmic targets. In HCT116 colon cancer cells and 224 melanoma cells, subapoptotic concentrations of cDDP induced a non-proliferative viable state (“senescence”). This was marginally blocked by inhibition of JNK and by scavengers of reactive oxygen species (ROS), whereas these inhibitors blocked apoptosis by both drugs. In contrast, OXP did not induce senescence and was able to induce apoptosis over a larger range of concentrations than cDDP, and did not as easily induce necrosis. Using HCT116 cells sensitive to apoptosis induction by both agents, and a panel of isogenic variants thereof, we investigated and compared apoptotic signaling induced by cDDP and OXP. The examined parameters include induction of ROS, nitric oxide and nitration, induction of superoxide and the roles therein of mitochondrial respiration and Rac1, and also the apoptotic involvement of peroxidation as a downstream effect of ROS and nitric oxide. Furthermore, p53 was in this system found to be required for apoptosis induced by OXP but not by cDDP. A model involving these results is presented which may shed light on the reasons for differential cellular sensitivities to cDDP and OXP, as well as on the nature of their induction of DNA-independent apoptosis.
Survival predictors of major salivary gland cancer
Authors: K.M. Elhusseiny, F.A.-E. Abd-Elhay, M.G. Kamel, H.H. Abd El Hamid Hassan, H.H. Muhammad El Tanany, H.T. Hong, T.M. Tieu, S.K. Low, V. Hou, M. Dibas, N.T. Huy
Journal: Annals of Oncology (2018)
Cost-effectiveness of Humanitarian Pediatric Cardiac Surgery Programs in Low- and Middle-Income Countries
Authors: Marcelo Cardarelli, Sumeet Vaikunth, Katie Mills, Thomas DiSessa, Frank Molloy, Elizabeth Sauter, Karen Bowtell, Roslyn Rivera, Andrew Y. Shin, William Novick
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Endorsement of global humanitarian interventions is based on either proven cost-effectiveness or perceived public health benefits. The cost-effectiveness and long-term benefits of global humanitarian pediatric cardiac surgery are unknown, and funding for this intervention is insufficient. <h3>Objectives</h3> To determine the cost-effectiveness of the intervention (multiple 2-week-long humanitarian pediatric cardiac surgery program assistance trips to various low- and middle-income countries [LMICs]) and to produce a measure of the long-lasting effects of global humanitarian programs. <h3>Design, Setting, and Participants</h3> International, multicenter cost-effectiveness analysis of a cohort of children (aged &lt;16 years) undergoing surgical treatment of congenital heart disease during 2015 in LMICs, including China, Macedonia, Honduras, Iran, Iraq, Libya, Nigeria, Pakistan, Russia, and Ukraine. The study also assessed estimated improvement in the United Nations Human Development Indicators (life expectancy, years of schooling, and gross national income) for each individual survivor, as a proxy for long-term benefits of the intervention. <h3>Main Outcomes and Measures</h3> The primary outcome was cost-effectiveness of the intervention. The secondary outcomes were potential gains in life expectancy, years of schooling, and gross national income per capita for each survivor. <h3>Results</h3> During 2015, 446 patients (192 [43%] female; mean [SD] age, 3.7 [5.4] years) were served in 10 LMICs at an overall cost of $3 210 873. Of them, 424 were children. The cost-effectiveness of the intervention was $171 per disability-adjusted life-year averted. Each survivor in the cohort (390 of 424) potentially gained 39.9 disability-adjusted life-years averted, 3.5 years of schooling, and $159 533 in gross national income per capita during his or her extended lifetime at purchasing power parity and 3% discounting. <h3>Conclusions and Relevance</h3> Humanitarian pediatric cardiac surgery in LMICs is highly cost-effective. It also leaves behind a lasting humanitarian footprint by potentially improving individual development indices.
Stable knockdown of endogenous STAT1 protein using retrovirus-mediated gene delivery of small hairpin RNAs
Authors: Elizabeth R. Quinn, Pat Collins, Susan Reynolds, John Apgar, Stephanie Widmann, Thomas P. Quinn, Laurence H. Lamarcq, Brad Scherer, Yen H. Nguyen, Daizong Li, Annick Le Gall, John F. Dunne
Journal: Cancer Research (2005)

4525  RNA interference (RNAi) is a sequence specific, post-transcriptional gene silencing process in which double-stranded, short inhibitory RNA sequences (siRNA) target and degrade native mRNA molecules. We have previously described a retroviral vector system that delivers a Polymerase III-driven expression cassette of double-stranded, short ‘hairpin’ RNAs (shRNAs), which are then cleaved by cellular enzymes to produce functional siRNAs capable of carrying out gene-specific silencing. In addition to the gene-specific shRNA, this vector has been engineered to constitutively express the DsRedExpress fluorescent protein, which allows for the direct detection of cells containing the shRNA. In this study, we examined the ability of a retroviral vector to encode shRNA directed against STAT1 as a means of providing long-term stable silencing of endogenous STAT1 protein in HeLa cells. Retroviral supernatants containing either STAT1 shRNA or an incomplete irrelevant hairpin (designated L4) were used to infect HeLa cells (MOI = 10). Forty-eight hours post-infection, the cultures were greater than 95% shRNA-positive based on equivalent DsRedExpress fluorescent protein expression. Both cell lines were expanded for thirty days and subsequently sorted on a BD FACSAria™ Flow Cytometer into Bright and Dim populations based on DsRedExpress fluorescent protein intensity. The mean fluorescence intensities of the Bright and the Dim populations expressing STAT1 shRNA differed by almost two orders of magnitude (75,739 and 870, respectively) on the day of the sort. Knockdown of endogenous STAT1 protein was confirmed at various time points using a Cytometric Bead Array (CBA) Assay, BD Mercury™ Transfactor STAT1 Assay, and Western blotting. In both the Bright and Dim populations, we observed greater than 90% knockdown of endogenous STAT1 protein, which persisted more than 130 days post-infection. Quantitation of total STAT1 protein levels by CBA and Western blotting demonstrated that the Dim populations expressed approximately 2-fold higher levels of STAT1 protein compared to the Bright populations. We believe this may be due to a moderate increase in STAT1 shRNA expression in the Bright populations, which could be the result of increased proviral copy number in these cells. This study demonstrates that retroviral-mediated shRNA delivery is a powerful method for studying persistent and stable knockdown of gene expression in mammalian cell types. Stable cell lines lacking specific gene products will provide useful tools for gene therapy and gene function studies.
Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers
Authors: Heather J. Landau, Gunjan L. Shah, Morgan Reeds, Patrick Hilden, Marci Andrejko, Alison Applebaum, Jason Batalha, Naomi Cazeau, David J. Chung, Melissa Cortes, Juliet Gerber Jenkelowitz, Christina Kiss, Sean M Devlin, Nicole Lestrange, Kathleen Lynch, Courtney McElrath, Dayna Palumbo, Elizabeth Schmidt Rodriguez, Michael Scordo, Sergio Giralt
Journal: Blood (2018)
The long noncoding RNA CHROME regulates cholesterol homeostasis in primates
Authors: Elizabeth J. Hennessy, Coen van Solingen, Kaitlyn R. Scacalossi, Mireille Ouimet, Milessa S. Afonso, Jurrien Prins, Graeme J. Koelwyn, Monika Sharma, Bhama Ramkhelawon, Susan Carpenter, Albert Busch, Ekaterina Chernogubova, Ljubica Perisic Matic, Ulf Hedin, Lars Maegdefessel, Brian E. Caffrey, Maryem A. Hussein, Emiliano P. Ricci, Ryan E. Temel, Michael J. Garabedian, Jeffrey S. Berger, Kasey C. Vickers, Matthew Kanke, Praveen Sethupathy, Daniel Teupser, Lesca M. Holdt, Kathryn J. Moore
Journal: Nature Metabolism (2018)
Composite End Points in Clinical Research
Authors: Paul W. Armstrong, Cynthia M. Westerhout
Journal: Circulation (2017)

Advances in cardiovascular medicine fueled by innovative clinical trials have dramatically improved the lives of patients worldwide. Commensurate with this progress has been a decline in morbid and mortal events. Accordingly, an increased propensity to collate patient outcomes in clinical trials has emerged that combines death and nonfatal complications into a single composite event. Despite the acknowledged benefits in trial efficiency from such an approach, this method assumes uniform directionality of each component, does not distinguish the relative clinical significance of each, and counts only the first occurrence of any event in the final tally within a conventional time to first event analysis. In this article, we evaluate the criticisms that have been leveled at this approach and provide an overview of recently published phase III cardiovascular trials using primary composite end points. We then explore what to anticipate from the large cohort of as-yet unpublished clinical trials in this arena. Last, we propose a variety of novel approaches that use composite end points and suggest a path forward to enhancing their use in future clinical trials.
Abstract 20394: Downstream Patterns of Revascularization Following Non-ST-Segment Elevation Acute Coronary Syndromes
Authors: Babatunde Yerokun, Matthew Roe, Jennifer White, Yuliya Lokhnygina, Andrew Tershakovec, Michael Blazing
Journal: Circulation (2017)

Background: Whether treatment with revascularization versus medical management (MM) around the index hospitalization for non-ST-elevation acute coronary syndromes (NSTE ACS) influences the long-ter...
Acquired resistance to immunotherapy in MMR-D pancreatic cancer
Authors: Zishuo Ian Hu, Matthew D. Hellmann, Jedd D. Wolchok, Monika Vyas, Jinru Shia, Zsofia K. Stadler, Luis A. Diaz, Eileen M. O’Reilly
Journal: Journal for ImmunoTherapy of Cancer (2018)

<h3>Background</h3> MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy. Here, we report the first case of acquired resistance to immunotherapy in MMR-D pancreatic cancer. <h3>Case presentation</h3> A 45-year-old woman with unresectable MMR-D pancreatic cancer was initially treated with FOLFIRINOX, FOLFIRI, and stereotactic body radiation with stable disease burden. After 3 months, imaging showed progression of disease with an increase in CA19-9. She was subsequently enrolled in a clinical trial of an anti-PD-L1 antibody in combination with an IDO1 inhibitor. She demonstrated a partial response to therapy by RECIST 1.1 criteria with declining tumor markers. Twenty-two months after beginning immunotherapy, imaging revealed an increasing left ovarian cystic mass. There were no other sites of progressive disease. The patient underwent a total hysterectomy and bilateral salpingo-oophorectomy, appendectomy, omentectomy and pelvic lymphadenopathy. Pathology was consistent with a metastasis from the pancreas involving the endometrium and left ovary. Thereafter, the patient continued with PD-1 blockade therapy off protocol with no further progressive disease. Immune profiling showed high levels of CD8+ T cells and PD-1 positive immune cells infiltrating the tumor, with a moderate level of PD-L1 expression in both the immune cells and the tumor cells. Next generation sequencing found only the <i>KRAS</i> G12D and <i>RNF43</i> G659Vfs*41 mutations were retained from the pre-treatment tumor in the treatment-resistant tumor. <h3>Conclusions</h3> This is the first report describing acquired resistance to immunotherapy in MMR-D pancreatic cancer with accompanying genomic and immune profiling. This case of oligoprogression in the setting of immunotherapy demonstrates the feasibility of localized treatment followed by continuation of immunotherapy to sustain ongoing response.
Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Authors: Marjorie Z. Imperial, Payam Nahid, Patrick P. J. Phillips, Geraint R. Davies, Katherine Fielding, Debra Hanna, David Hermann, Robert S. Wallis, John L. Johnson, Christian Lienhardt, Rada M. Savic
Journal: Nature Medicine (2018)
Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation
Authors: D. Bessis, J. Miquel, E. Bourrat, C. Chiaverini, F. Morice‐Picard, C. Abadie, F. Manna, C. Baumann, M. Best, P. Blanchet, A.‐C. Bursztejn, Y. Capri, C. Coubes, F. Giuliano, S. Guillaumont, S. Hadj‐Rabia, M.‐L. Jacquemont, C. Jeandel, D. Lacombe, S. Mallet, J. Mazereeuw‐Hautier, N. Molinari, V. Pallure, C. Pernet, N. Philip, L. Pinson, P. Sarda, S. Sigaudy, Y. Vial, M. Willems, D. Geneviève, A. Verloes, H. Cavé
Journal: British Journal of Dermatology (2018)

Data on dermatological manifestations of Noonan syndrome (NS) remain heterogeneous and are based on limited dermatological expertise. To describe the dermatological manifestations of NS, compare them with the literature findings, and test for dermatological phenotype–genotype correlations with or without the presence of PTPN11 mutations. We performed a large 4‐year, prospective, multicentric, collaborative dermatological and genetic study. Overall, 129 patients with NS were enrolled, including 65 patients with PTPN11‐NS, 34 patients with PTPN11‐NS with multiple lentigines (NSML), and 30 patients with NS who had a mutation other than PTPN11. Easy bruising was the most frequent dermatological finding in PTPN11‐NS, present in 53·8% of patients. Multiple lentigines and café‐au‐lait macules (n ≥ 3) were present in 94% and 80% of cases of NSML linked to specific mutations of PTPN11, respectively. Atypical forms of NSML could be associated with NS with RAF1 or NRAS mutations. In univariate analysis, patients without a PTPN11 mutation showed (i) a significantly higher frequency of keratinization disorders (P = 0·001), including keratosis pilaris (P = 0·005), ulerythema ophryogenes (P = 0·0001) and palmar and/or plantar hyperkeratosis (P = 0·06, trend association), and (ii) a significantly higher frequency of scarce scalp hair (P = 0·035) and scarce or absent eyelashes (P = 0·06, trend association) than those with PTPN11 mutations. The cutaneous phenotype of NS with a PTPN11 mutation is generally mild and nonspecific, whereas the absence of a PTPN11 mutation is associated with a high frequency of keratinization disorders and hair abnormalities.
원저 : 정맥류 출혈에 의한 사망 및 재출혈 예측 인자의 유용성 비교: Child-Pugh 점수, MELD 점수, Rockall 점수
Authors: 이자영, 이진헌, 김수진, Dae Ro Choi, 김경호, 김용범, 김학양, 유재영
Journal: Clinical and Molecular Hepatology (2002)

목적: 정맥류 출혈 중 특히 초출혈은 높은 사망률을 보이는 간경변증의 합병증이지만 최근에는 여러 치료법의 발전으로 사망률의 감소 경향을 보이고 있다. 출혈시 예후 예측에 있어 Child-Pugh(CP) 점수는 가장 널리 쓰이는 방법이며, 최근 간이식의 시행과 더불어 Model for End-Stage Liver Disease(MELD) 점수를 CP 점수에 대신하여 적용하려는 시도가 있다. 또한 급성 상부 위장관 출혈 환자의 사망률 및 재출혈 위험을 알아보기 위한 Rockall 점수는 정맥류를 포함한 모든 상부 위장관 출혈의 예측 인자로 알려져 있다. 본 연구에서는 간경변증의 합병증 중 높은 치사율과 사망률을 보이는 정맥류 출혈, 특히 초출혈에 있어 사망률 및 재발율을 알아보고, 이의 예후를 예측하는 데 있어, CP 점수, MELD 점수 및 Rockall 점수의 유용성을 비교해 보고자 하였다. 대상과 방법: 1998년 1월부터 2000년 12월까지 정맥류 초출혈로 인한 혈변 및 토혈을 주소로 내원하여 내시경을 시행한 136명의 환자 중 간세포암과 동반된 35명과 1ss 후 추적 관찰이 불가능한 8명의 환자는 제외한 93명을 대상으로, 환자의 나이, 성별, 간경변증의 원인과 CP 점수, MELD 점수, Rockall 점수를 측정하였고, 모든 환자는 초출혈후 6주 이내의 사망 여부 및 재출혈 여부를 확인하였으며, 생존 환자의 경우 출혈 후 1년 사망 여부에 대하여 확인하였다. 결과: 대상 환자 93명 중, 정맥류 출혈 6주 이내의 사망률은 24.7%, 재출혈율은 12.9%, 1년 사망률은 35.5%였다. 6주 사망률 예측에 대한 CP 점수의 c-statitstics는 0.809 (p<0.001, 95% CI, 0.720-0.898), MELD 점수는 0.804(p<0.001 95% CI, 0.696-0.911), Rockall 점수는 0.787(p<0.001, 95% CI, 0.683-0.890)였고, 1년 사망률은 각각 0.765(p<0.005, 95% CI, 0.665-0.865), 0.780(p<0.005, 95% CI, 0.676-0.883), 0.730(p<0.01, 95% CI, 0.627-0.834)였다. 결론: 정맥류 초출혈 시 6주, 1년 내 사망의 예측에 있어서 CP 점수, MELD 점수 및 Rockall 점수는 유용하게 적용할 수 있으나, 분류의 간편함 등을 고려하여 재출혈을 제외한 6주 이내, 1년 사망의 예측에 있어서는 CP 점수가 편리하게 사용할 수 있을 것으로 판단된다.
Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer
Authors: J.T. Wang, H. Li, H. Zhang, Y.F. Chen, Y.F. Cao, R.C. Li, C. Lin, Y.C. Wei, X.N. Xiang, H.J. Fang, H.Y. Zhang, Y. Gu, X. Liu, R.J. Zhou, H. Liu, H.Y. He, W.J. Zhang, Z.B. Shen, J. Qin, J.J. Xu
Journal: Annals of Oncology (2018)
Pooled RCTs: Low-dose ASA reduced CV events in persons &amp;lt; 70 kg; higher-dose ASA was effective at higher body weights
Authors: Steven D. Stovitz
Journal: Annals of Internal Medicine (2018)

Source Citation Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392:387-99. 30017552
Abstract 15537: Left Ventricular Diastolic Dysfunction and Metabolic Risk Factors in Mexican Americans
Authors: Neha M Paul, Kristina P Vatcheva, Beverly Smulevitz, Emma Molina, David D McPherson, Joseph B McCormick, Susan P Fisher-Hoch, Susan T Laing
Journal: Circulation (2017)

Left ventricular diastolic dysfunction (LVDD) is a key element in the clinical syndrome of heart failure with preserved ejection fraction; subclinical LVDD is a predictor of incident overt heart fa...